Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETILDEX Gel vs Solution in Cataract Surgery
NCT02973880Phase 3Completed
- Sponsor
- SIFI SpA
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of netilmicin + dexamethasone in ocular inflammation and bacterial eye infection (2 arms), sponsored by SIFI SpA. Primary endpoint: Measurement of inflammation conditions in the anterior ocular chamber at 9 weeks. Started Oct 2017; status: completed.
02
Drugs
netilmicin + dexamethasone
03
Conditions
ocular inflammationbacterial eye infection
Beyond the preview
Go deeper on NCT02973880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973880.